JW Pharmaceutical Corp
KRX:001060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
JW Pharmaceutical Corp
KRX:001060
|
KR |
|
Daitron Co Ltd
TSE:7609
|
JP |
|
S
|
Srithai Superware PCL
SET:SITHAI
|
TH |
|
Westlake Corp
NYSE:WLK
|
US |
|
Elliptic Laboratories ASA
OSE:ELABS
|
NO |
|
T
|
Totm Technologies Ltd
SGX:42F
|
SG |
|
Sovereign Metals Ltd
ASX:SVM
|
AU |
|
D
|
Daea TI Co Ltd
KOSDAQ:045390
|
KR |
|
Technoprobe SpA
MIL:TPRO
|
IT |
|
Surgery Partners Inc
NASDAQ:SGRY
|
US |
Wall Street
Price Targets
Price Targets Summary
JW Pharmaceutical Corp
According to Wall Street analysts, the average 1-year price target for
JW Pharmaceutical Corp
is 34 680 KRW
with a low forecast of 34 340 KRW and a high forecast of 35 700 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is JW Pharmaceutical Corp's stock price target?
Price Target
34 680
KRW
According to Wall Street analysts, the average 1-year price target for
JW Pharmaceutical Corp
is 34 680 KRW
with a low forecast of 34 340 KRW and a high forecast of 35 700 KRW.
What is JW Pharmaceutical Corp's Revenue forecast?
Projected CAGR
7%
For the last 14 years the
compound annual growth rate for
JW Pharmaceutical Corp's revenue is
4%.
The projected
CAGR
for the next 3 years is
7%.
What is JW Pharmaceutical Corp's Operating Income forecast?
Projected CAGR
11%
For the last 14 years the
compound annual growth rate for
JW Pharmaceutical Corp's operating income is
13%.
The projected
CAGR
for the next 3 years is
11%.
What is JW Pharmaceutical Corp's Net Income forecast?
Projected CAGR
21%
The
compound annual growth rate
of JW Pharmaceutical Corp's net income for the next 3 years is
21%.
